TYROBP and cancer: In a word, our study identified a conserved SPI1-TYROBP-FCER1G network across cancer types for the first time, and explored its immune-related mechanism in OS, which could be used as a treatment target in OS with TNF-α or TYROBP/FCER1G stimulators to rescue the under-expression of SPI1-TYROBP-FCER1G network in OS.